H.R. 9599 is a proposed bill aimed at strengthening the 340B Drug Pricing Program, which allows certain healthcare providers to purchase outpatient drugs at discounted prices to support services for low-income and uninsured patients. The bill seeks to enhance transparency and oversight within the program by implementing stricter reporting requirements for participating hospitals and clinics. This includes detailed disclosures on how the savings from discounted drug purchases are utilized to benefit patients. Additionally, the bill proposes measures to prevent pharmaceutical manufacturers from imposing restrictions on the distribution of 340B drugs through contract pharmacies, ensuring that covered entities can continue to serve their communities effectively. By addressing these issues, H.R. 9599 aims to preserve the integrity and intended purpose of the 340B program.
Supporters of H.R. 9599, including various healthcare organizations and patient advocacy groups, have praised the bill for promoting greater transparency and accountability within the 340B program. They argue that the proposed reporting requirements will help ensure that the benefits of the program are directly reaching the patients it is designed to serve. Furthermore, the bill's provisions to prevent drug manufacturers from limiting the use of contract pharmacies are seen as a crucial step in maintaining access to affordable medications for underserved communities. These measures are viewed as essential for sustaining the financial viability of safety-net providers and for continuing to offer comprehensive services to vulnerable populations.
Critics of H.R. 9599, particularly from the pharmaceutical industry, have expressed concerns that the bill imposes burdensome reporting requirements on healthcare providers, potentially diverting resources away from patient care. They also argue that restricting manufacturers' ability to manage the distribution of 340B drugs could lead to inefficiencies and increased costs within the drug supply chain. Some stakeholders worry that the bill does not adequately address the complexities of the 340B program and may inadvertently create new challenges for both providers and manufacturers. Additionally, there is apprehension that the bill could exacerbate existing tensions between drug manufacturers and healthcare providers, leading to further disputes over program implementation and compliance.
The analysis of H.R. 9599, aimed at strengthening the 340B drug discount program, reveals no direct industry overlaps between the sponsor Scott Peters' top donor industries and the bill's subject matter. The top donor industries do not appear to have a vested interest in the pharmaceutical sector, which is the primary focus of the 340B program. While there is significant lobbying activity in the healthcare space, particularly from the American Dental Association with $1,100,000 and Cellebrite Inc. with $70,000, these contributions do not indicate a direct conflict with the intent of the bill. The absence of contributions from pharmaceutical companies or related entities further supports the low risk assessment. Voters should be aware that while lobbying exists, it does not directly correlate to the sponsors' financial backers in this instance.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| AMERICAN DENTAL ASSOCIATION | AMERICAN DENTAL ASSOCIATION | $1,100,000 |
| CELLEBRITE INC. | CELLEBRITE INC. | $70,000 |
| ANIMAL HEALTH INSTITUTE | ANIMAL HEALTH INSTITUTE | $55,000 |
| SAFE KIDS WORLDWIDE | SAFE KIDS WORLDWIDE | $25,000 |
| AMERICAN CONCRETE PIPE ASSOCIATION | EDMUND GRABER | $20,000 |
| MATERIALS RESEARCH SOCIETY | HILLSTAFFER, LLC | $15,000 |
| NAFA FLEET MANAGEMENT ASSOCIATION | HILLSTAFFER, LLC | $15,000 |
| BETTENDORF IA | EDMUND GRABER | $10,000 |
| NATIONAL UTILITY CONTRACTORS ASSN | EDMUND GRABER | $10,000 |
| ILLINOIS PUBLIC TRANSIT ASSN | EDMUND GRABER | $10,000 |
| NATIONAL COOPERATIVE BUSINESS ASSOCIATION | NATIONAL COOPERATIVE BUSINESS ASSOCIATION | undisclosed |
| FMC CORPORATION | RED FLAG CONSULTING USA(FORMALLY KNOWN AS INTERNATIONAL BUSINESS-GOVERNMENT COUNSELLORS, INC) | undisclosed |
| ASSOCIATION FOR DIPLOMATIC STUDIES AND TRAINING | HILLSTAFFER, LLC | undisclosed |
| NATIONAL ACADEMY OF NEUROPSYCHOLOGY | HILLSTAFFER, LLC | undisclosed |
| THE ETHYLENE OXIDE STERILIZATION ASSOCIATION, INC | HILLSTAFFER, LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Scott Peters, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
